Spotlight on Internal Medicine

Credits: 0.25 CME
Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach
Parambir S. Dulai, MD
AGA Institute

Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Dana Lukin, MD, PhD
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Dana Lukin, MD, PhD
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Internal Medicine Presentations

Chloe Orkin, MBBCH, MSc, FRCP
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 3: HIV in Women

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 3: HIV in Women

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

Women with HIV require care outside of traditional HIV management, particularly concerning pregnancy and contraceptives. Clinicians require updates on new data and guidelines about appropriate antiretroviral therapy (ART) regimens during pregnancy as well as strategies for multidisciplinary care. Dr. Chloe Orkin and Dr. Sharon L. Walmsley discuss a patient who is virally suppressed and would like to conceive. They discuss ART regimens, viral monitoring, collaboration with an obstetrician/gynecologist, intra- and postpartum care, breastfeeding, and contraceptives.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

Women with HIV require care outside of traditional HIV management, particularly concerning pregnancy and contraceptives. Clinicians require updates on new data and guidelines about appropriate antiretroviral therapy (ART) regimens during pregnancy as well as strategies for multidisciplinary care. Dr. Chloe Orkin and Dr. Sharon L. Walmsley discuss a patient who is virally suppressed and would like to conceive. They discuss ART regimens, viral monitoring, collaboration with an obstetrician/gynecologist, intra- and postpartum care, breastfeeding, and contraceptives.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Richard A. Elion, MD
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 5: Controversies in Managing Resistance

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 5: Controversies in Managing Resistance

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure

Activity Description

Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia


Jürgen Rockstroh, MD
Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure

Activity Description

Though first-line antiretroviral therapy (ART) regimens have high barriers to resistance, it is still important to obtain genotyping for newly diagnosed patients and for those experiencing virologic failure. There is evidence that patients with a variety of resistance mutations can still achieve viral suppression, though regimen selection may be influenced by resistance mutations. Dr. Richard A. Elion and Dr. Jürgen Rockstroh discuss a newly diagnosed patient with baseline resistance mutations in the context of treatment initiation, switching, impact of specific mutations, and how resistance mutations influence selection of either 2-drug or long-acting therapies.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia


Jürgen Rockstroh, MD
Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn
Bonn, Germany

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Jürgen Rockstroh, MD: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Theratechnologies Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Chloe Orkin, MBBCH, MSc, FRCP
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 4: Heavily Treatment-Experienced Patients

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
  • Review recent data on new and emerging ART regimens

Activity Description

As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Jonathan Schapiro, MD
Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: December 3, 2021
Expires: December 3, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Address the challenges faced when selecting subsequent ART regimens in patients experiencing virologic failure
  • Review recent data on new and emerging ART regimens

Activity Description

As patients with HIV live longer, clinicians must work with heavily treatment-experienced patients who are experiencing virologic failure and have few treatment options left. Though this is a small population, their subsequent antiretroviral therapy (ART) regimens should be tailored carefully and may need to employ new ART agents as they become available. Dr. Chloe Orkin and Dr. Jonathan Schapiro discuss a heavily treatment-experienced patient in the context of resistance mutations, Stanford score, considerations for subsequent regimens, and new and emerging options for these patients.

Faculty

Chloe Orkin, MBBCH, MSc, FRCP
Consultant Physician and Lead for HIV Research
Professor of HIV Medicine
Queen Mary University of London and Barts Health NHS Trust
Director, SHARE Collaborative
Academic Lead for Equality, Diversity, and Inclusion SMD
President, Medical Women’s Federation
London, United Kingdom


Jonathan Schapiro, MD
Director
HIV/AIDS Clinic
National Hemophilia Center
Sheba Medical Center
Tel Aviv, Israel

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Chloe Orkin, MBBCH, MSc, FRCP: Consulting Fees: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., ViiV Healthcare

Jonathan Schapiro, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Contracted Research: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education; Speakers Bureau: AbbVie Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., ViiV Healthcare, Virology Education

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Julie V. Philley, MD
0.25 CME / MOC
RMEI Medical Education, LLC
Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Start
Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX


Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO


Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX


Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO


Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Julie V. Philley, MD
0.25 CME / MOC
RMEI Medical Education, LLC
Challenging Cases in NTM-LD: Refractory MAC and Medication Intolerance

Challenging Cases in NTM-LD: Refractory MAC and Medication Intolerance

Start
Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases involving Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into the application of evidence and guideline-based treatment for refractory MAC lung disease, highlighting their unique roles in the interprofessional management of medication intolerance.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX


Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO


Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: November 24, 2021
Expires: November 23, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for pulmonology and infectious disease clinicians (MD/NP/PA) who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
  • Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Description

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases involving Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into the application of evidence and guideline-based treatment for refractory MAC lung disease, highlighting their unique roles in the interprofessional management of medication intolerance.

Faculty

Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX


Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO


Tara Sadler, APRN, MSN, FNP-C
Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Charles L. Daley, MD, has financial relationships with AN2, Insmed, Matinas, Paratek, Spero (Advisor); BugWorks, Insmed, Paratek (Grant/Research Support).

Julie V. Philley, MD, has financial relationships with AN2, Electromed, Paratek (Consultant); AN2, Electromed, Hillrom, Insmed, Paratek, RedHill, Regeneron, Zambon (Researcher); France Foundation, Insmed (Speaker’s Bureau).

Tara Sadler, APRN, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 67% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Cassandra Calabrese, DO
0.5 CME / MOC / CPE
Vindico Medical Education
Pneumococcal Disease: Prevalence and Prevention – A Wheel of Knowledge Challenge!

Pneumococcal Disease: Prevalence and Prevention – A Wheel of Knowledge Challenge!

Start

Activity Details

Free CME/MOC/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
0.5 ACPE Contact Hour(s)
Released: November 15, 2021
Expires: November 14, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for this activity is family medicine physicians, internists, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the management of patients with pneumococcal disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the burden of pneumococcal disease and patient populations who are at high risk for disease.
  • Incorporate the safe and effective use of pneumococcal disease vaccination, as per Advisory Committee on Immunization Practices (ACIP) recommendations, in both normal- and high-risk patients.
  • Utilize effective strategies that educate patients about pneumococcal disease and increase their vaccine confidence.

Activity Description

Pneumococcal disease poses a burden to the community throughout the year, especially in those with chronic underlying conditions. Due to the high persistent burden of disease, pneumococcal pneumonia—particularly non-bacteremic pneumococcal pneumonia—continues to be a major public health concern. Young children and the elderly are especially at risk for pneumococcal disease and are therefore eligible for immunization in most countries. However, clinicians are often unaware of the burden of pneumococcal disease and the patient populations who are at highest risk for disease. They also may lack understanding of the safe and effective use of pneumococcal disease vaccination and may not know how to utilize effective strategies to educate patients about pneumococcal disease and increase their vaccine confidence. Moreover, clinicians may not be aware of the current guideline recommendations for best practices regarding the use of pneumococcal vaccination, and they may be unaware of the new and emerging pneumococcal vaccines, thus resulting in suboptimal care for their patients. In this game-based CME activity, participants will answer questions on the burden of pneumococcal disease, the latest ACIP recommendations regarding the optimal use of pneumococcal disease strategies in both normal- and high-risk patients, as well as strategies to educate patients about pneumococcal disease.

Activity Co-Chairs

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Consultant: Sanofi Genzyme
Speaker Contracted by Ineligible Company: Sanofi Genzyme


John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure:
Advisor: Sanofi
Speaker Contracted by Ineligible Company: Sanofi

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-026-H01-P, effective 11/15/2021. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 0.5 hour(s) credit for completing this program.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
0.5 ACPE Contact Hour(s)
Released: November 15, 2021
Expires: November 14, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for this activity is family medicine physicians, internists, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the management of patients with pneumococcal disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the burden of pneumococcal disease and patient populations who are at high risk for disease.
  • Incorporate the safe and effective use of pneumococcal disease vaccination, as per Advisory Committee on Immunization Practices (ACIP) recommendations, in both normal- and high-risk patients.
  • Utilize effective strategies that educate patients about pneumococcal disease and increase their vaccine confidence.

Activity Description

Pneumococcal disease poses a burden to the community throughout the year, especially in those with chronic underlying conditions. Due to the high persistent burden of disease, pneumococcal pneumonia—particularly non-bacteremic pneumococcal pneumonia—continues to be a major public health concern. Young children and the elderly are especially at risk for pneumococcal disease and are therefore eligible for immunization in most countries. However, clinicians are often unaware of the burden of pneumococcal disease and the patient populations who are at highest risk for disease. They also may lack understanding of the safe and effective use of pneumococcal disease vaccination and may not know how to utilize effective strategies to educate patients about pneumococcal disease and increase their vaccine confidence. Moreover, clinicians may not be aware of the current guideline recommendations for best practices regarding the use of pneumococcal vaccination, and they may be unaware of the new and emerging pneumococcal vaccines, thus resulting in suboptimal care for their patients. In this game-based CME activity, participants will answer questions on the burden of pneumococcal disease, the latest ACIP recommendations regarding the optimal use of pneumococcal disease strategies in both normal- and high-risk patients, as well as strategies to educate patients about pneumococcal disease.

Activity Co-Chairs

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Consultant: Sanofi Genzyme
Speaker Contracted by Ineligible Company: Sanofi Genzyme


John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure:
Advisor: Sanofi
Speaker Contracted by Ineligible Company: Sanofi

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-026-H01-P, effective 11/15/2021. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 0.5 hour(s) credit for completing this program.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

David Malebranche, MD, MPH
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 1: Long-Acting Injectables

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 1: Long-Acting Injectables

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: November 8, 2021
Expires: November 8, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is intended for HIV specialists engaged in the care of patients with HIV.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
  • Review recent data on new and emerging ART regimens

Activity Description

Recent advances in antiretroviral therapy have led to the advent of long-acting injectables (LAIs) to treat HIV. Clinicians have many questions about safety, efficacy, and implementation, as well as questions about how best to select and educate patients. Dr. David Malebranche and Dr. Raphael J. Landovitz discuss a patient who may be a candidate for an LAI and address common questions about patient selection and education, oral lead-in, dosing considerations, missed doses, injection site reactions, and clinic protocols.

Faculty

David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia


Raphael J. Landovitz, MD, MSC
Professor of Medicine
UCLA Center for Clinical AIDS Research & Education
Center Co-Director
Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Core Co-Director
CHIPTS Combination Prevention Core
Los Angeles, California

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

Raphael J. Landovitz, MD, MSC: Consulting Fees: Cepheid, Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: November 8, 2021
Expires: November 8, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is intended for HIV specialists engaged in the care of patients with HIV.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
  • Review recent data on new and emerging ART regimens

Activity Description

Recent advances in antiretroviral therapy have led to the advent of long-acting injectables (LAIs) to treat HIV. Clinicians have many questions about safety, efficacy, and implementation, as well as questions about how best to select and educate patients. Dr. David Malebranche and Dr. Raphael J. Landovitz discuss a patient who may be a candidate for an LAI and address common questions about patient selection and education, oral lead-in, dosing considerations, missed doses, injection site reactions, and clinic protocols.

Faculty

David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia


Raphael J. Landovitz, MD, MSC
Professor of Medicine
UCLA Center for Clinical AIDS Research & Education
Center Co-Director
Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Core Co-Director
CHIPTS Combination Prevention Core
Los Angeles, California

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

Raphael J. Landovitz, MD, MSC: Consulting Fees: Cepheid, Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

David Malebranche, MD, MPH
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 2: Adolescents and Young Adults Newly Diagnosed with HIV

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 2: Adolescents and Young Adults Newly Diagnosed with HIV

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: November 8, 2021
Expires: November 8, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is intended for HIV specialists engaged in the care of patients with HIV.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

Adolescents and young adults newly diagnosed with HIV often necessitate some different management strategies compared with adults. This can range from treatment selection to transitioning from a pediatric clinic to an adult HIV clinic. Many providers who are accustomed to treating adults are not fully prepared for caring for an adolescent patient. Dr. David Malebranche and Dr. David C. Griffith discuss a newly diagnosed adolescent and address common questions about discussing an HIV diagnosis, ART selection and considerations for future adverse events, and educating about adherence, refilling prescriptions, mental health, and transitioning to an adult clinic.

Faculty

David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia


David C. Griffith, MD
Assistant Professor of Medicine
The Johns Hopkins University School of Medicine
Medical Director, Clinical Associate
Johns Hopkins AIDS Service County Program
Baltimore, Maryland

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

David C. Griffith, MD: Consulting Fees: Gilead Sciences, Inc.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: November 8, 2021
Expires: November 8, 2022
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is intended for HIV specialists engaged in the care of patients with HIV.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

Adolescents and young adults newly diagnosed with HIV often necessitate some different management strategies compared with adults. This can range from treatment selection to transitioning from a pediatric clinic to an adult HIV clinic. Many providers who are accustomed to treating adults are not fully prepared for caring for an adolescent patient. Dr. David Malebranche and Dr. David C. Griffith discuss a newly diagnosed adolescent and address common questions about discussing an HIV diagnosis, ART selection and considerations for future adverse events, and educating about adherence, refilling prescriptions, mental health, and transitioning to an adult clinic.

Faculty

David Malebranche, MD, MPH
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia


David C. Griffith, MD
Assistant Professor of Medicine
The Johns Hopkins University School of Medicine
Medical Director, Clinical Associate
Johns Hopkins AIDS Service County Program
Baltimore, Maryland

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.

David C. Griffith, MD: Consulting Fees: Gilead Sciences, Inc.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must score 100% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Culley C. Carson,  MD, FACS, FRCS(hon)
1.0 CME / MOC
Vindico Medical Education
Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Peyronie's Disease: Staying Ahead of the Curve With Recent Advances in Treatment

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
Released: October 31, 2021
Expires: October 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, urologists, and other health care professionals involved in the management of patients with Peyronie’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Recognize the burden of Peyronie’s disease and the need for increased awareness of the condition.
  • Incorporate the use of screening and patient history to aide in prompt diagnosis, treatment, or referral for patients with Peyronie’s disease.
  • Apply knowledge about conventional, new, and emerging treatments for Peyronie’s disease, their benefits and limitations, as well as how they can be best incorporated into clinical practice.

Activity Description

Generalized Peyronie’s disease (PD) is a localized fibrotic disorder of the tunica albuginea resulting in penile pain, plaque, indentation, curvature, deformity, or shortening during erection. Additionally, some men will also experience erectile dysfunction. There are 2 distinct stages of PD: the acute stage characterized by pain, and during which the disease may progress; and the chronic stage, which occurs 6 to 12 months later, when pain resolves and the deformity stabilizes. Unfortunately, data have demonstrated that most individuals with PD do not receive adequate health care from clinicians. This insufficient care is attributed to numerous factors, including clinicians lacking awareness of the burden of PD, not having a good understanding of its etiology to better recognize the need for patient screening and complete history, as well as not staying up to date about conventional and new treatments for PD. In this educational activity, expert clinicians provide the latest updates on diagnosis and management of PD. 

Agenda

Introduction
Culley C. Carson, MD, FACS, FRCS(hon)

The Burden of Peyronie’s Disease
Ashley H. Tapscott, DO

Etiology and Diagnosis
Joel J. Heidelbaugh, MD, FAAFP, FACG

Treatment of Peyronie’s Disease
Culley C. Carson, MD, FACS, FRCS(hon)

Activity Chair

Culley C. Carson, MD, FACS, FRCS(hon)
Rhodes Distinguished Professor and Chair of Urology (emeritus)
University of North Carolina
Chapel Hill, NC

Disclosure:
Consultant: Boston Scientific, Endo Pharmaceuticals
Speakers Bureau: Boston Scientific, Endo Pharmaceuticals

Faculty

Joel J. Heidelbaugh, MD, FAAFP, FACG
Clinical Professor
Departments of Family Medicine and Urology
University of Michigan Medical School
Ann Arbor, MI

Disclosure: No relevant financial relationships to disclose.


Ashley H. Tapscott, DO
Founder and Director
The Sexual Health Institute of the Carolinas
Carolina Urology Partners
Huntersville, NC

Disclosure:
Consultant: Coloplast, Endo Pharmaceuticals

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty for Peyronie’s Disease: Staying Ahead of the Curve With Recent Advances in Treatment have provided the above disclosure information, which is accurate at the time of publishing.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Endo Pharmaceuticals Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Roy S. Herbst, MD, PhD
0.75 CME / MOC
RMEI Medical Education, LLC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pages